Baidu
map

Cell Metabolism:高胰岛素水平可导致肥胖

2012-12-20 Cell Metabolism 互联网 liuygi

一个意外的发现表明,某些有关健康饮食的普遍的想法可能是错误的,实际上却能导致人们体重增加。 这个发现来自一位来自英国的哥伦比亚大学的研究人员,并被发表在《细胞代谢》杂志上。 该研究起初是观察胰岛素的作用的试验,胰岛素是一种激素,能使机体储存血糖以便作为能量以后使用。胰岛素缺乏能导致糖尿病,而且,根据同杂志发表的一项不同研究,胰岛素主要作用受损,可能引起无限制的脂肪分解,而更严重地,这将导致2型

一个意外的发现表明,某些有关健康饮食的普遍的想法可能是错误的,实际上却能导致人们体重增加。

这个发现来自一位来自英国的哥伦比亚大学的研究人员,并被发表在《细胞代谢》杂志上。

该研究起初是观察胰岛素的作用的试验,胰岛素是一种激素,能使机体储存血糖以便作为能量以后使用。胰岛素缺乏能导致糖尿病,而且,根据同杂志发表的一项不同研究,胰岛素主要作用受损,可能引起无限制的脂肪分解,而更严重地,这将导致2型糖尿病。

细胞生理学副教授詹姆斯.约翰逊在分析了动物体内胰岛素的作用后,发现过多的胰岛素可能是有害的。

约翰逊将小鼠分成两组,两组都喂给高脂饮食。一组为对照组,由正常小鼠组成,另一组由被培育为仅有半数胰岛素的小鼠组成。

结果显示,正常小鼠超重,这就像科学家所预料的。然而,低水平胰岛素小鼠体重并没有增加,这是由于它们的脂肪细胞代谢了更多的能量,而使储存变少了。依然很瘦的小鼠没有变胖,并能更健康地生活。

这意味着,依据约翰逊的发现,高脂饮食所引起的正常小鼠额外增加的胰岛素导致了肥胖。换言之,和人一样,小鼠或许产生了过多的胰岛素。

该研究表明,人们能通过时常地将胰岛素水平带回到健康所需的最小量来维持一个健康体重。这可以通过增加两餐间隔时间和不吃零食,不在进餐时间过度饮食。

一般的认为,为了保持苗条,人们每天应该吃少量食物,但在这项研究中显示,这是无效的。

约翰逊结论

“胰岛素对储存血糖很重要,它也能将好事变成坏事。如果我们能将胰岛素水平维持在敲到好处,我们将扭转肥胖的高发,肥胖是许多疾病的一个危险因素,如糖尿病、心脏疾病和癌症。”

胰岛素和肥胖之间的关系令人惊讶

鉴于UBC生命科学研究所约翰逊并没有实施检测肥胖的研究,因而他对他的发现感到相当惊讶。他最初着手确定,是否胰腺β细胞(胰岛素分泌细胞)因本身的胰岛素分泌被促进增加了。

约翰逊的两个发现时意料之外的:

l低胰岛素小鼠不增加体重

l这些小鼠中多数(甚至显着降低胰岛素水平)仍然没有发展成糖尿病

根据2007-2009年测量的身高和体重数据,估计加拿大每4个人中就有1个是肥胖的。从1981年到2007-2009年,在几个年龄段中,男性和女性的肥胖率增加了两倍。

虽然,有药物能限制胰岛素,并防止人们增加体重,但它们的副作用却抵消了用药的优势。因此,需要做更多的研究,以便能发现阻止人们产生额外的胰岛素或者改变对特异靶组织影响的药物。

胰岛素相关的拓展阅读:

DOI:10.1016/j.cmet.2012.10.019,
PMC:
PMID:

Hyperinsulinemia Drives Diet-Induced Obesity Independently of Brain Insulin Production

Arya E. Mehran1, 2, Nicole M. Templeman1, 2, G. Stefano Brigidi1, Gareth E. Lim1, 2, Kwan-Yi Chu1, 2, Xiaoke Hu1, 2, Jose Diego Botezelli1, 2, Ali Asadi1, 2, Bradford G. Hoffman2, Timothy J. Kieffer1, 2, Shernaz X. Bamji1, Susanne M. Clee1, James D. Johnson1, 2

Hyperinsulinemia is associated with obesity and pancreatic islet hyperplasia, but whether insulin causes these phenomena or is a compensatory response has remained unsettled for decades. We examined the role of insulin hypersecretion in diet-induced obesity by varying the pancreas-specific Ins1 gene dosage in mice lacking Ins2 gene expression in the pancreas, thymus, and brain. Age-dependent increases in fasting insulin and β cell mass were absent in Ins1+/−:Ins2−/− mice fed a high-fat diet when compared to Ins1+/+:Ins2−/− littermate controls. Remarkably, Ins1+/−:Ins2−/− mice were completely protected from diet-induced obesity. Genetic prevention of chronic hyperinsulinemia in this model reprogrammed white adipose tissue to express uncoupling protein 1 and increase energy expenditure. Normalization of adipocyte size and activation of energy expenditure genes in white adipose tissue was associated with reduced inflammation, reduced fatty acid spillover, and reduced hepatic steatosis. Thus, we provide genetic evidence that pathological circulating hyperinsulinemia drives diet-induced obesity and its complications.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958842, encodeId=a20b1958842b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Apr 10 00:51:00 CST 2013, time=2013-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887334, encodeId=7257188e334f6, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Mar 23 21:51:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895650, encodeId=b2a51895650b3, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 05 20:51:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868608, encodeId=17911868608ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Nov 25 14:51:00 CST 2013, time=2013-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749388, encodeId=22531e4938828, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Nov 29 08:51:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577137, encodeId=3a7215e713785, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Sat Dec 22 05:51:00 CST 2012, time=2012-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597915, encodeId=f978159e915bf, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Sat Dec 22 05:51:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
    2013-04-10 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958842, encodeId=a20b1958842b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Apr 10 00:51:00 CST 2013, time=2013-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887334, encodeId=7257188e334f6, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Mar 23 21:51:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895650, encodeId=b2a51895650b3, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 05 20:51:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868608, encodeId=17911868608ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Nov 25 14:51:00 CST 2013, time=2013-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749388, encodeId=22531e4938828, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Nov 29 08:51:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577137, encodeId=3a7215e713785, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Sat Dec 22 05:51:00 CST 2012, time=2012-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597915, encodeId=f978159e915bf, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Sat Dec 22 05:51:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
    2013-03-23 guojianrong
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958842, encodeId=a20b1958842b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Apr 10 00:51:00 CST 2013, time=2013-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887334, encodeId=7257188e334f6, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Mar 23 21:51:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895650, encodeId=b2a51895650b3, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 05 20:51:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868608, encodeId=17911868608ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Nov 25 14:51:00 CST 2013, time=2013-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749388, encodeId=22531e4938828, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Nov 29 08:51:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577137, encodeId=3a7215e713785, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Sat Dec 22 05:51:00 CST 2012, time=2012-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597915, encodeId=f978159e915bf, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Sat Dec 22 05:51:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
    2013-06-05 一闲
  4. [GetPortalCommentsPageByObjectIdResponse(id=1958842, encodeId=a20b1958842b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Apr 10 00:51:00 CST 2013, time=2013-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887334, encodeId=7257188e334f6, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Mar 23 21:51:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895650, encodeId=b2a51895650b3, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 05 20:51:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868608, encodeId=17911868608ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Nov 25 14:51:00 CST 2013, time=2013-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749388, encodeId=22531e4938828, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Nov 29 08:51:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577137, encodeId=3a7215e713785, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Sat Dec 22 05:51:00 CST 2012, time=2012-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597915, encodeId=f978159e915bf, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Sat Dec 22 05:51:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1958842, encodeId=a20b1958842b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Apr 10 00:51:00 CST 2013, time=2013-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887334, encodeId=7257188e334f6, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Mar 23 21:51:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895650, encodeId=b2a51895650b3, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 05 20:51:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868608, encodeId=17911868608ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Nov 25 14:51:00 CST 2013, time=2013-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749388, encodeId=22531e4938828, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Nov 29 08:51:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577137, encodeId=3a7215e713785, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Sat Dec 22 05:51:00 CST 2012, time=2012-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597915, encodeId=f978159e915bf, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Sat Dec 22 05:51:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
    2013-11-29 baoya
  6. [GetPortalCommentsPageByObjectIdResponse(id=1958842, encodeId=a20b1958842b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Apr 10 00:51:00 CST 2013, time=2013-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887334, encodeId=7257188e334f6, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Mar 23 21:51:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895650, encodeId=b2a51895650b3, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 05 20:51:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868608, encodeId=17911868608ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Nov 25 14:51:00 CST 2013, time=2013-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749388, encodeId=22531e4938828, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Nov 29 08:51:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577137, encodeId=3a7215e713785, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Sat Dec 22 05:51:00 CST 2012, time=2012-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597915, encodeId=f978159e915bf, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Sat Dec 22 05:51:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1958842, encodeId=a20b1958842b0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Apr 10 00:51:00 CST 2013, time=2013-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887334, encodeId=7257188e334f6, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Mar 23 21:51:00 CST 2013, time=2013-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895650, encodeId=b2a51895650b3, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Jun 05 20:51:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868608, encodeId=17911868608ea, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Nov 25 14:51:00 CST 2013, time=2013-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749388, encodeId=22531e4938828, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Fri Nov 29 08:51:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577137, encodeId=3a7215e713785, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Sat Dec 22 05:51:00 CST 2012, time=2012-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597915, encodeId=f978159e915bf, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Sat Dec 22 05:51:00 CST 2012, time=2012-12-22, status=1, ipAttribution=)]
    2012-12-22 闆锋旦

相关资讯

MCP:定量蛋白质组学确定转移性肾细胞癌的生物标志物

  近日,圣迈克尔医院George M Yousef博士于12月6日发布在Molecular & Cellular Proteomics上的一项新研究确定了参与肾细胞癌蔓延转移的29个蛋白。这一发现将帮助医生识别哪些肿瘤会表现得更加具有侵略性,并能帮助更深入的治疗患者。   George M Yousef博士说:转移性

Cancer Cell:治疗转移性乳腺癌旨在解决耐药性

研究人员在本月11日发表在《癌细胞》杂志上的一项小鼠试验显示,未来人们有望在转移性乳腺癌治疗道路上迈出坚实的一步。研究结果强调,基础癌症生物学对于推进疗效好毒副作用低的治疗取得进展具有重要意义。瑞士弗雷德里克-米歇尔研究所研究员Mohamed Bentires-Alj表示:“我们需要更深入的探究肿瘤细胞的构造并掌握其耐性机制,以便提出正确的联合疗法。此外,我们还需要就肿瘤发生转移的机制进行研究。”

Cell Metab:日研究阐明非酒精性脂肪肝发病机制

7月4日,日本横滨市立大学和大阪大学的联合研究小组宣布,他们首次弄清了非酒精性脂肪肝的发病机制。他们确认,一些肥胖者的肝脏会与肠内的细菌发生过敏反应,从而导致肝部发病。 非酒精性脂肪肝多由肥胖引起。它是指患者无饮酒史,但病理学上和酒精性脂肪肝患者有相似的病理状态,比如也有肝细胞脂肪变性、肝小叶炎症,有时也有“酒精”玻璃样变性和肝纤维化等。 研究人员在动物实验中发现,实验鼠肥胖后,脂肪细胞大量分

NCB:神奇蛋白防癌抗衰

一场从发现一只快速老化的小鼠开始的、不同寻常的、持续10年的旅程让科学家找到了这样一种蛋白。这种蛋白保护动物远离癌症和衰老所带来的各种折磨,并且这种蛋白没有明显的缺陷。 这种命名为BubR1的蛋白目前还有许多谜需要科学家去揭开,但是这项工作为研究如何保护染色体、提升健康水平提供了线索。 美国明尼苏达州罗彻斯特梅奥诊所的癌症生物学家Jan van Deursen和他的同事最初的兴趣在于研究癌症的

Cell Metabolism:激素治疗糖尿病,激素

近日,杜克大学医学中心研究人员发现激素可以像胰岛素那样由胰腺中的胰岛细胞产生,产生的激素具有保护功效、抗糖尿病的功能。发现新的激素能刺激老鼠和人类胰岛细胞胰岛素的分泌,能保护胰岛细胞免受毒性因子、细胞杀伤因子的损害。 这项最新研究刊登在7月3日的Cell Metabolism杂志上。 研究人员给予TLQP-21朱克糖尿病脂肪老鼠激素,这种老鼠有罹患2型糖尿病的遗传倾向。研究结果给予激素的老鼠体

Cell:高蛋白膳食如何使大脑形成饱腹感?

一顿高蛋白大餐后,我们通常有一种饱腹感,最具代表性的就是皮带越来越紧的不舒服感,其实饱腹感涉及的内容不仅仅是这样,那么,这种饱腹感是如何产生的了?发表于7月5日Cell上的一篇研究解答了上述问题,它把消化道与大脑之间的饱足感信号通路描绘了出来,了解大脑与消化道间的这种往返回路可能为将来肥胖症治疗和预防铺平道路。 食物摄入由神经纤维上的Mu阿片受体(MORs,也可结合吗啡)调节,该受体主要分布于门

Baidu
map
Baidu
map
Baidu
map